ERBB2 and breast cancer: Besides, trastuzumab deruxtecan has demonstrated very remarkable activity in patients with metastatic HER-2-positive BC, with an objective response rate (ORR) of almost 60% in patients that were previously refractory to T-DM1 (Table 1) [29].